Lung Cancer
Volume 67, Issue 2 , Pages 248-250, February 2010

Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event

  • Shotaro Ide

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
  • ,
  • Hiroshi Soda

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 956 24 1515; fax: +81 956 22 4641.
  • ,
  • Tomoaki Hakariya

      Affiliations

    • Division of Urology, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
  • ,
  • Shinnosuke Takemoto

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
  • ,
  • Hiroshi Ishimoto

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
  • ,
  • Shinya Tomari

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
  • ,
  • Toyomitsu Sawai

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
  • ,
  • Seiji Nagashima

      Affiliations

    • Division of Respiratory Medicine, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
  • ,
  • Masataka Furukawa

      Affiliations

    • Division of Urology, Sasebo City General Hospital, 9-3 Hirase, Sasebo, Nagasaki 857-8511, Japan
  • ,
  • Yoichi Nakamura

      Affiliations

    • Department of Second Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
  • ,
  • Shigeru Kohno

      Affiliations

    • Department of Second Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

Received 6 February 2009; received in revised form 24 August 2009; accepted 8 October 2009. published online 09 November 2009.

Abstract 

There has been no literature which reports a case of interstitial lung disease associated with sorafenib. However, a recent post-marketing survey in Japan revealed that interstitial pneumonia occurred in 4 among approximately 2 000 Japanese patients treated with sorafenib. In this article, we describe a Japanese patient with severe interstitial pneumonia probably caused by sorafenib treatment for metastatic renal cell carcinoma. Oncologists supervising future clinical trials for lung cancer should be alert to the fact that sorafenib can potentially induce serious interstitial lung disease, although this might depend on racial differences.

Keywords: Sorafenib, Interstitial pneumonia, Racial differences, Ground-glass opacity, Crazy-paving pattern, Surfactant protein

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(09)00535-2

doi:10.1016/j.lungcan.2009.10.007

Lung Cancer
Volume 67, Issue 2 , Pages 248-250, February 2010